Patents by Inventor Janelle Noble

Janelle Noble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of susceptibility to autoimmune diseases
    Publication number: 20070105146
    Abstract: The present invention provides methods and reagents for determining sequence variants present at the IL4 receptor, IL-4 and IL-13 loci, which facilitate identifying individuals at risk for type 1 diabetes.
    Type: Application
    Filed: December 11, 2006
    Publication date: May 10, 2007
    Applicant: Roche Molecular Systems, Inc.
    Inventors: Daniel Mirel, Henry Erlich, Teodorica Bugawan, Janelle Noble, Ana Valdes
  • Association of polymorphisms in IL4-related genes with autoimmune disease
    Patent number: 7205106
    Abstract: The present invention provides methods and reagents for determining sequence variants present at the IL4 receptor, IL-4 and IL-13 loci, which facilitate identifying individuals at risk for type 1 diabetes.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: April 17, 2007
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Daniel B. Mirel, Henry A. Erlich, Teodorica L. Bugawan, Janelle A. Noble, Ann Maria Valdes
  • IL-4 receptor sequence variation associated with type 1 diabetes
    Publication number: 20030152951
    Abstract: The present invention provides methods and reagents for determining sequence variants present at the IL4R locus, which facilitates identifying individuals at risk for type 1 diabetes.
    Type: Application
    Filed: July 3, 2002
    Publication date: August 14, 2003
    Inventors: Daniel B. Mirel, Henry A. Erlich, Teodorica L. Bugawan, Janelle A. Noble, Ana Maria Valdez
  • Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof
    Patent number: 6156300
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 5, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof
    Patent number: 6117422
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
    Patent number: 5681719
    Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N- 3 deletion mutants of the long form of CSF-1
    Patent number: 5672343
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 30, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N-.gradient.3 deletion mutants of the short form of CSF-1
    Patent number: 5643563
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: July 1, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding various forms of colony stimulating factor-1
    Patent number: 5573930
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: November 12, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths